Study to Evaluate Switching From a Regimen Consisting of a Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

Status:	Archived
Conditions:	HIV / AIDS
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	Any
Updated:	7/1/2011
Start Date:	January 2011
End Date:	July 2012

A Phase 2B Open Label Pilot Study to Evaluate Switching From a Regimen Consisting of a Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV 1 Infected Subjects

The purpose of this pilot study is to evaluate the efficacy and safety of FTC/RPV/TDF STR
after switching from EFV/FTC/TDF at baseline in maintaining HIV-1 RNA < 50 copies/mL at week
12. HIV-infected patients who have been receiving EFV/FTC/TDF for greater than or equal to
3 months and are experiencing safety or tolerability concerns (in particular,
efavirenz-related intolerance) may wish to change to an alternate, better tolerated regimen.

We found this trial at

sites

Whitman Walker Clinic

Washington, District of Columbia

from

Washington,